Miltenyi Biotec– tag –
-
Point-of-Care Manufacturing Accelerates for Cell and Gene Therapies; Lonza Cocoon Sale Reshapes Industry Landscape
BioPharm International International Overview Point-of-care (PoC) manufacturing for biopharmaceuticals, particularly cell and gene therapies, is gaining momentum, with systems like Lonza's Cocoon and Miltenyi Biotec's CliniMACS Prodigy p... -
Cracking the Cost Code: Cellares’ Automated Platform Targets 75% Reduction in CAR-T Manufacturing, Pinpointing Viral Vectors as Key Driver
IntuitionLabs USA Overview A new analysis highlights viral vectors as the primary cost driver in CAR-T cell therapy manufacturing, prompting an urgent need for more efficient production. While existing closed-system platforms offer incre... -
Cell Therapy Consumables Market Set for $7.53 Billion Surge by 2032, Fueled by Automation and Closed Systems
Credence Research India Overview A new report from Credence Research projects the global cell therapy consumables market will reach $7.53 billion by 2032. This significant growth is primarily driven by the expanding adoption of advanced ... -
Miltenyi Biotec’s CliniMACS Prodigy® Automates TIL Expansion, Paving Way for Scalable Cancer Immunotherapy
Bioprocess Online Germany Overview Miltenyi Biotec is advancing the automated expansion of tumor-infiltrating lymphocytes (TILs) using its GMP-compliant CliniMACS Prodigy® platform. This system addresses critical challenges in scaling up... -
Pre-owned Miltenyi Biotec CliniMACS Instrument Hits Secondary Market, Broadening Access to Advanced Cell Separation
LabX.com USA Overview A used Miltenyi Biotec CliniMACS Instrument cell separator (Model 44085), manufactured in October 2017, has been listed on the online lab equipment marketplace LabX.com. This sophisticated device is engineered for e... -
Point-of-Care Cell Therapy Manufacturing Surges Forward with Miltenyi Biotec’s CliniMACS Prodigy and Octane Medical’s Cocoon Systems
BioPharm International USA Overview Miltenyi Biotec's CliniMACS Prodigy and Octane Medical Group's Cocoon systems are emerging as pivotal technologies for accelerating point-of-care (PoC) manufacturing in cell therapy. These modular, clo... -
Scalable Automation in Adherent-Cell Cultures Boosts Yield and Quality: Corning’s HYPERStack and CellCube Systems Key to Efficiency
BioProcess International USA Overview Automation in scaling out adherent cell cultures significantly enhances consistency, proving especially effective where labor and bioprocessing expertise are limited. Automated culture platforms impr... -
Catalent Bolsters End-to-End CDMO Services for Autologous & Allogeneic Cell Therapies, Including iPSC Center of Excellence
Catalent USA Overview Catalent is enhancing its end-to-end CDMO manufacturing support and process development services for both autologous and allogeneic cell therapies, covering CAR-T, TCR, TIL, NK cells, and iPSC- and MSC-derived treat... -
EU-Funded S.O.L.A.R.I.S. Project Launched to Enhance Scalability, Efficiency, and Sustainability of CAR T Cell Manufacturing Across Europe
Green Elephant Biotech Germany Overview The EU-funded S.O.L.A.R.I.S. Project has commenced with 13 partners, including Green Elephant Biotech and Miltenyi Biotec, aiming to develop and implement new approaches for scalable, efficient, an... -
Jordan Advances Global CAR-T Access with High-Efficiency Point-of-Care Manufacturing Using CliniMACS Prodigy
ASCO Publications Jordan Overview In a significant step towards democratizing advanced cell therapies, point-of-care manufacturing of anti-CD19.1 CAR-T cells using the Miltenyi CliniMACS Prodigy system was successfully demonstrated in Jo...
12